Diabetes and cardiometabolic diseases are highly associated with NAFLD5–9 and therefore these data further support the hypothesis that NAFLD is involved in reduced clopidogrel efficacy through the downregulation of CYP2C19. This evidence concerns the gene CYP2C19 and diabetes mellitus.